

Howard H Feldman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6825664/publications.pdf>

Version: 2024-02-01

150
papers

50,267
citations

15466

65
h-index

9073

144
g-index

164
all docs

164
docs citations

164
times ranked

38040
citing authors

#	ARTICLE	IF	CITATIONS
1	The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 270-279.	0.4	7,498
2	Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. <i>Science</i> , 2006, 314, 130-133.	6.0	5,422
3	Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. <i>Neuron</i> , 2011, 72, 245-256.	3.8	4,176
4	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. <i>Lancet Neurology</i> , The, 2007, 6, 734-746.	4.9	3,755
5	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.5	2,805
6	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , The, 2014, 13, 614-629.	4.9	2,657
7	Mild cognitive impairment. <i>Lancet</i> , The, 2006, 367, 1262-1270.	6.3	2,401
8	Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. <i>Nature</i> , 2006, 442, 916-919.	13.7	1,816
9	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.4	1,318
10	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , The, 2016, 15, 455-532.	4.9	1,242
11	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016, 87, 539-547.	1.5	1,216
12	Nonpharmacological Therapies in Alzheimer's Disease: A Systematic Review of Efficacy. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 161-178.	0.7	720
13	Treatment of Alzheimer's disease; current status and new perspectives. <i>Lancet Neurology</i> , The, 2003, 2, 539-547.	4.9	664
14	Dementia with Lewy bodies. <i>Lancet Neurology</i> , The, 2004, 3, 19-28.	4.9	645
15	Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. , 2011, 7, 367-385.		531
16	Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. <i>Human Molecular Genetics</i> , 2006, 15, 2988-3001.	1.4	529
17	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. <i>Nature Genetics</i> , 2010, 42, 234-239.	9.4	479
18	Sortilin-Mediated Endocytosis Determines Levels of the Frontotemporal Dementia Protein, Progranulin. <i>Neuron</i> , 2010, 68, 654-667.	3.8	465

#	ARTICLE	IF	CITATIONS
19	Candidate Single-Nucleotide Polymorphisms From a Genomewide Association Study of Alzheimer Disease. <i>Archives of Neurology</i> , 2008, 65, 45-53.	4.9	443
20	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology</i> , The, 2021, 20, 484-496.	4.9	396
21	Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. <i>Neurobiology of Aging</i> , 2012, 33, 1203-1214.e2.	1.5	346
22	Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. <i>Lancet Neurology</i> , The, 2007, 6, 501-512.	4.9	314
23	Safety and Tolerability of the β -Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 1430.	4.9	314
24	Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. <i>Lancet</i> , The, 2016, 388, 2873-2884.	6.3	299
25	Cholesterol in Alzheimer's disease. <i>Lancet Neurology</i> , The, 2005, 4, 841-852.	4.9	292
26	The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. <i>Brain</i> , 2006, 129, 3081-3090.	3.7	291
27	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. <i>Human Molecular Genetics</i> , 2008, 17, 3631-3642.	1.4	271
28	Worldwide FINGERS Network: A global approach to risk reduction and prevention of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 1078-1094.	0.4	257
29	The Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease. <i>Focus (American Psychiatric Publishing)</i> , 2013, 11, 96-106.	0.4	241
30	Emerging Therapies for Vascular Dementia and Vascular Cognitive Impairment. <i>Stroke</i> , 2004, 35, 1010-1017.	1.0	212
31	Efficacy of Donepezil on Behavioral Symptoms in Patients With Moderate to Severe Alzheimer's Disease. <i>International Psychogeriatrics</i> , 2002, 14, 389-404.	0.6	211
32	Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. <i>Brain</i> , 2012, 135, 709-722.	3.7	201
33	Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C>T (Arg493X) mutation: an international initiative. <i>Lancet Neurology</i> , The, 2007, 6, 857-868.	4.9	199
34	Diagnosis and treatment of dementia: 2. Diagnosis. <i>Cmaj</i> , 2008, 178, 825-836.	0.9	196
35	Efficacy of Donepezil on Maintenance of Activities of Daily Living in Patients with Moderate to Severe Alzheimer's Disease and the Effect on Caregiver Burden. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 737-744.	1.3	189
36	Targeting Prodromal Alzheimer Disease With Avagacestat. <i>JAMA Neurology</i> , 2015, 72, 1324.	4.5	179

#	ARTICLE	IF	CITATIONS
37	Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 196-203.	0.9	170
38	The Spectrum of Mutations in Progranulin. <i>Archives of Neurology</i> , 2010, 67, 161-70.	4.9	166
39	Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. <i>Nature Medicine</i> , 1996, 2, 1230-1235.	15.2	165
40	The rights of precision drug development for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 76.	3.0	148
41	Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2006, 20, 732-755.	2.0	145
42	Apolipoprotein E ϵ 4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. <i>Cmaj</i> , 2004, 171, 863-867.	0.9	144
43	Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. <i>Depression and Anxiety</i> , 2010, 27, 417-425.	2.0	144
44	Synaptic dysfunction in progranulin-deficient mice. <i>Neurobiology of Disease</i> , 2012, 45, 711-722.	2.1	144
45	Ubiquitin Immunohistochemistry Suggests Classic Motor Neuron Disease, Motor Neuron Disease With Dementia, and Frontotemporal Dementia of the Motor Neuron Disease Type Represent a Clinicopathologic Spectrum. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 730-739.	0.9	143
46	Potential for misclassification of mild cognitive impairment: A study of memory scores on the Wechsler Memory Scale-III in healthy older adults. <i>Journal of the International Neuropsychological Society</i> , 2008, 14, 463-478.	1.2	140
47	Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. <i>Alzheimer's Research and Therapy</i> , 2013, 5, S2.	3.0	129
48	Epidemiology and genetics of frontotemporal dementia/Pick's disease. <i>Annals of Neurology</i> , 2003, 54, S29-S31.	2.8	120
49	Neuropsychological testing and assessment for dementia. <i>Alzheimer's and Dementia</i> , 2007, 3, 299-317.	0.4	112
50	Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration. <i>Archives of Neurology</i> , 2011, 68, 488.	4.9	108
51	Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 559-569.	1.3	105
52	A family with tau-negative frontotemporal dementia and neuronal intranuclear inclusions linked to chromosome 17. <i>Brain</i> , 2006, 129, 853-867.	3.7	102
53	Can we prevent Alzheimer's disease? Secondary prevention trials in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2013, 9, 123.	0.4	100
54	Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019, 137, 209-226.	3.9	100

#	ARTICLE	IF	CITATIONS
55	Therapeutic potential of statins in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2009, 283, 230-234.	0.3	99
56	Mild Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 645-655.	0.6	95
57	Cognition, Function, and Caregiving Time Patterns in Patients With Mild-to-Moderate Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2005, 19, 29-36.	0.6	94
58	Clinical phenotypes of Cerebral Amyloid Angiopathy. <i>Journal of the Neurological Sciences</i> , 2007, 257, 23-30.	0.3	93
59	Mild cognitive impairment. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 645-55.	0.6	88
60	The Consortium to Investigate Vascular Impairment of Cognition: Methods and First Findings. <i>Canadian Journal of Neurological Sciences</i> , 2003, 30, 237-243.	0.3	86
61	Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1056-1063.	0.9	81
62	rs5848 polymorphism and serum progranulin level. <i>Journal of the Neurological Sciences</i> , 2011, 300, 28-32.	0.3	77
63	Periventricular hyperintensities are associated with elevated cerebral amyloid. <i>Neurology</i> , 2016, 86, 535-543.	1.5	75
64	Differentiating the frontal variant of Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 732-738.	1.3	73
65	Superficial Siderosis. <i>Stroke</i> , 2008, 39, 2894-2897.	1.0	72
66	Activities of Daily Living in Moderate-to-Severe Alzheimer Disease: An Analysis of the Treatment Effects of Memantine in Patients Receiving Stable Donepezil Treatment. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, 263-268.	0.6	67
67	Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 479-488.	1.3	64
68	Prevention trials in Alzheimer's disease: An EU-US task force report. <i>Progress in Neurobiology</i> , 2011, 95, 594-600.	2.8	62
69	Dependence as a unifying construct in defining Alzheimer's disease severity. <i>Alzheimer's and Dementia</i> , 2010, 6, 482-493.	0.4	61
70	Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. <i>Neurology</i> , 2013, 81, 1322-1331.	1.5	60
71	Pharmacodynamics of Selective Inhibition of β -Secretase by Avagacestat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 686-695.	1.3	59
72	Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development. <i>Alzheimer's and Dementia</i> , 2013, 9, 176-188.	0.4	58

#	ARTICLE	IF	CITATIONS
73	The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics. <i>Alzheimer's and Dementia</i> , 2008, 4, 145-153.	0.4	56
74	The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 499-511.	0.3	56
75	Outcomes of Cognitively Impaired Not Demented at 2 Years in the Canadian Cohort Study of Cognitive Impairment and Related Dementias. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 413-420.	0.7	53
76	Synergistic effect of apolipoprotein E ϵ 4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 289-298.	0.7	49
77	Minimizing Misdiagnosis: Psychometric Criteria for Possible or Probable Memory Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 439-450.	0.7	49
78	The advantages of frontotemporal degeneration drug development (part of frontotemporal) Tj ETQq0 0 0 rgBT (Overlock 10 Tf 50 54	0.4	48
79	A Randomized, Controlled Trial of Linopirdine in the Treatment of Alzheimer's Disease. <i>Canadian Journal of Neurological Sciences</i> , 1997, 24, 140-145.	0.3	47
80	The relationship between extramotor ubiquitin-immunoreactive neuronal inclusions and dementia in motor neuron disease. <i>Acta Neuropathologica</i> , 2003, 105, 98-102.	3.9	47
81	Evaluation of late-onset Alzheimer disease genetic susceptibility risks in a Canadian population. <i>Neurobiology of Aging</i> , 2014, 35, 936.e5-936.e12.	1.5	47
82	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. <i>Alzheimer's and Dementia</i> , 2020, 16, 131-143.	0.4	45
83	Effectiveness of Donepezil in Reducing Clinical Worsening in Patients with Mild-to-Moderate Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 244-251.	0.7	44
84	Canadian Guidelines for the Development of Antidementia Therapies: a Conceptual Summary. <i>Canadian Journal of Neurological Sciences</i> , 1995, 22, 62-72.	0.3	42
85	Effect of diesel exhaust inhalation on blood markers of inflammation and neurotoxicity: a controlled, blinded crossover study. <i>Inhalation Toxicology</i> , 2016, 28, 145-153.	0.8	39
86	A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. <i>Nature Communications</i> , 2021, 12, 7065.	5.8	38
87	Neuronal intranuclear inclusions distinguish familial FTD-MND type from sporadic cases. <i>Acta Neuropathologica</i> , 2003, 105, 543-548.	3.9	37
88	Disease progression in vascular cognitive impairment: Cognitive, functional and behavioural outcomes in the Consortium to Investigate Vascular Impairment of Cognition (CIVIC) cohort study. <i>Journal of the Neurological Sciences</i> , 2007, 252, 106-112.	0.3	36
89	An exploration of cognitive subgroups in Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2010, 16, 233-243.	1.2	35
90	Clinical and radiographic subtypes of vascular cognitive impairment in a clinic-based cohort study. <i>Journal of the Neurological Sciences</i> , 2006, 240, 7-14.	0.3	33

#	ARTICLE	IF	CITATIONS
91	Sleep and its regulation: An emerging pathogenic and treatment frontier in Alzheimer's disease. <i>Progress in Neurobiology</i> , 2021, 197, 101902.	2.8	33
92	Alzheimer's disease research and development: a call for a new research roadmap. <i>Annals of the New York Academy of Sciences</i> , 2014, 1313, 1-16.	1.8	31
93	Safety and Efficacy of Edonepic Maleate for Patients With Mild to Moderate Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 1330.	4.5	29
94	Cognitive heterogeneity in probable Alzheimer disease. <i>Neurology</i> , 2019, 93, e778-e790.	1.5	27
95	What are the Treatment Options for Patients with Severe Alzheimer's Disease?. <i>CNS Drugs</i> , 2004, 18, 575-583.	2.7	26
96	Transition from Cognitively Impaired Not Demented to Alzheimer's Disease: An Analysis of Changes in Functional Abilities in a Dementia Clinic Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 483-490.	0.7	26
97	Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study. <i>Journal of the Neurological Sciences</i> , 2010, 288, 142-146.	0.3	26
98	A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. <i>Progress in Neurobiology</i> , 2013, 110, 114-123.	2.8	26
99	Gray matter changes in asymptomatic C9orf72 and GRN mutation carriers. <i>NeuroImage: Clinical</i> , 2018, 18, 591-598.	1.4	26
100	Fatal Familial Insomnia. <i>Archives of Neurology</i> , 2004, 61, 122.	4.9	25
101	Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned?. , 2006, 2, 220-233.		25
102	Neuropsychiatric Symptom Clusters and Functional Disability in Cognitively-Impaired-Not-Demented Individuals. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 136-144.	0.6	25
103	Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY). <i>Alzheimer's Research and Therapy</i> , 2018, 10, 102.	3.0	24
104	Delayed daily activity and reduced NREM slow-wave power in the APPswe/PS1dE9 mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 78, 74-86.	1.5	24
105	Extrapyramidal features in patients with motor neuron disease and dementia; a clinicopathological correlative study. <i>Acta Neuropathologica</i> , 2004, 107, 336-340.	3.9	23
106	Neuronal Intranuclear Inclusions Distinguish Familial FTD-MND Type from Sporadic Cases. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 333-336.	0.7	22
107	Revised research diagnostic criteria for Alzheimer's disease. <i>Lancet Neurology</i> , The, 2008, 7, 668-670.	4.9	21
108	Pharmacological treatment in moderate-to-severe Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2575-2582.	0.9	21

#	ARTICLE	IF	CITATIONS
109	Rates of Cognitive Change in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 357-364.	0.6	21
110	Early Neuropsychological Characteristics of Progranulin Mutation Carriers. <i>Journal of the International Neuropsychological Society</i> , 2014, 20, 694-703.	1.2	21
111	Therapeutic trial design for frontotemporal dementia and related disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 412-423.	0.9	21
112	Clinical Presentation of Prodromal Frontotemporal Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2008, 22, 456-467.	0.9	20
113	Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach. <i>Gender Medicine</i> , 2009, 6, 345-355.	1.4	20
114	Premature termination codon readthrough upregulates progranulin expression and improves lysosomal function in preclinical models of GRN deficiency. <i>Molecular Neurodegeneration</i> , 2020, 15, 21.	4.4	19
115	Cognitive Impairment No Dementia "Neuropsychological and Neuroimaging Characterization of an Amnesic Subgroup. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 238-247.	0.7	18
116	The 2002 NIMH Provisional Diagnostic Criteria for Depression of Alzheimer's Disease (PDC-dAD): Gauging their Validity over a Decade Later. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 449-462.	1.2	18
117	PROGRESS IN CLINICAL NEUROSCIENCES: Canadian Guidelines for the Development of Antidementia Therapies: A Conceptual Summary. <i>Canadian Journal of Neurological Sciences</i> , 2006, 33, 6-26.	0.3	17
118	Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1907.	1.0	15
119	Global issues in drug development for Alzheimer's disease. , 2011, 7, 197-207.		14
120	Value-Generating Exploratory Trials in Neurodegenerative Dementias. <i>Neurology</i> , 2021, 96, 944-954.	1.5	14
121	Neuropsychological Subgroups of Cognitively-Impaired-Not-Demented (CIND) Individuals: Delineation, Reliability, and Predictive Validity. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2005, 27, 164-188.	0.8	13
122	Primary Prevention and Delay of Onset of AD/Dementia. <i>Canadian Journal of Neurological Sciences</i> , 2007, 34, S84-S89.	0.3	13
123	Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 707-713.	1.2	12
124	Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12071.	1.8	12
125	The Canadian dementia challenge: Ensuring optimal care and services for those at risk or with dementia throughout the country. <i>Canadian Journal of Public Health</i> , 2017, 108, e95-e97.	1.1	11
126	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease. <i>Nature Communications</i> , 2022, 13, 1495.	5.8	11

#	ARTICLE	IF	CITATIONS
127	Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2022, 79, 565.	4.5	11
128	Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial. <i>Alzheimer's and Dementia</i> , 2018, 14, 1397-1405.	0.4	10
129	Neuropsychological Characterization of Cognitively-Impaired-Not-Demented (CIND) Individuals: Clinical Comparison Data. <i>Clinical Neuropsychologist</i> , 2004, 18, 208-228.	1.5	8
130	Atlas of Alzheimer's Disease. , 0, , .		7
131	New lexicon and criteria for the diagnosis of Alzheimer's disease " Authors' reply. <i>Lancet Neurology</i> , The, 2011, 10, 300-301.	4.9	7
132	Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease. <i>BMC Neurology</i> , 2006, 6, 32.	0.8	6
133	Assessing the validity of deriving clinical dementia rating (CDR) global scores from independently-obtained functional rating scale (FRS) scores in vascular dementia with and without Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 1174-1176.	1.3	6
134	Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab. <i>Canadian Geriatrics Journal</i> , 2021, 24, 373-378.	0.7	6
135	A randomized clinical trial to evaluate home-based assessment of people over 75 years old. <i>Alzheimer's and Dementia</i> , 2019, 15, 615-624.	0.4	5
136	Predicting response to acetylcholinesterase inhibitor treatment in Alzheimer disease: has the time come?. <i>Nature Reviews Neurology</i> , 2009, 5, 128-129.	4.9	4
137	Neurobehavioral characterization of adult-onset Alexander disease. <i>Neurology: Clinical Practice</i> , 2017, 7, 425-429.	0.8	4
138	16-Year Survival of the Canadian Collaborative Cohort of Related Dementias. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 367-374.	0.3	3
139	Committee on High-Equality Alzheimer's Disease Studies (CHADS) consensus report. <i>Alzheimer's and Dementia</i> , 2022, 18, 1109-1118.	0.4	3
140	Applying the Alzheimer Disease ATN Diagnostic Framework in Atypical Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2020, 34, 357-359.	0.6	3
141	Impact of potential modifications to Alzheimer's disease clinical trials in response to disruption by COVID-19: a simulation study. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 201.	3.0	3
142	Early Identification of Alzheimer's Disease: What Have we Learned from Mild Cognitive Impairment?. <i>CNS Spectrums</i> , 2008, 13, 4-7.	0.7	2
143	Output of the working group on magnetic resonance imaging abnormalities and treatment with amyloid-modifying agents. <i>Alzheimer's and Dementia</i> , 2011, 7, 365-366.	0.4	2
144	Drug Treatment: Cholinesterase Inhibitors. , 2006, , 131-149.		1

#	ARTICLE	IF	CITATIONS
145	Canadian Guidelines for the Development of Antidementia Therapies: 2nd Canadian Conference on Antidementia Drug Guidelines. Canadian Journal of Neurological Sciences, 2007, 34, i-S2.	0.3	1
146	F5-03-02: Perspective from the clinical research and manufacturing communities. , 2013, 9, P826-P826.		0
147	IC-P-108: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODRIMAL AD POPULATION. , 2014, 10, P60-P61.		0
148	P4-038: CREATION OF THE CANADIAN CONSORTIUM FOR NEURODEGENERATION IN AGING. , 2014, 10, P796-P796.		0
149	P2-202: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODRIMAL AD POPULATION. , 2014, 10, P546-P547.		0
150	F5-03-02: Biomarkers are Useful in Tertiary Care Clinical Decision-Making. Alzheimer's and Dementia, 2016, 12, P370.	0.4	0